At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
AD036 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
In Brief
A Phase 2 clinical trial evaluating AD036, Atomoxetine, and 1 other intervention for Obstructive Sleep Apnea. Completed, enrolled 62 participants across 5 sites.
Detailed Summary
This is a randomized, 3-Period, Placebo-Controlled, Crossover, phase 2 clinical study to examine the efficacy and safety of AD036 versus placebo or atomoxetine in patients with obstructive sleep apnea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionDec 2020
TodayJul 2026
First PostedJun 24, 2020
Enrollment StartJul 15, 2020
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.0 years ago
Interventions
AD036drug
Oral administration before bed
Atomoxetinedrug
Oral administration before bed
Placebodrug
Oral administration before bed